Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

NCT03507348 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped investigateur decision

Conditions

End-stage Renal Disease
Kidney Transplantation
Hla-incompatible Kidney Transplant Candidates

Interventions

DRUG: visits of tocilizumab injection (every 4 weeks, up to 5 visits)
DRUG: Rituximab 375 mg/m2 at Day-30
DRUG: Rituximab 375 mg/m2 at Day-15 (only for donors living)
OTHER: Transplant Day-0

Sponsor

University Hospital, Grenoble